# Trade Mark Journal No.2025/027 4 July 2025

## WO0000001860329 (1,5,42)

Office of origin: United States of America

Date of International Registration:21 April 2025
Date of designation in the UK: 21 April 2025

International priority date claimed: 21 October 2024 (United States of America) (98811175)

Class 1
  Diagnostic preparations for scientific or research use other than for medical use; assays and reagents for scientific or medical research use; genetic testing preparations for scientific or medical research use, namely, assays and reagents for use in genetic and biomedical research; cells for scientific or medical research use.
Class 5
  Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical products; pharmaceutical preparations for treating genetic diseases and disorders; pharmaceutical preparations for treating and lysosomal storage disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the reproductive system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart diseases and disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases and disorders; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in urology; pharmaceutical preparations for the prevention and treatment of obesity; pharmaceutical preparations for ophthalmological use; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical products for the prevention and treatment of bone diseases; pharmaceutical products for the prevention and treatment of respiratory diseases and asthma; reagents for medical use; genetic testing preparations for medical purposes, namely, medical diagnostic reagents and assays for testing of body fluids, cells, and tissue; cells for medical or clinical use; medical diagnostic and testing assays, namely, medical diagnostic reagents and assays for testing of body fluids, cells, and tissue.
Class 42
  Pharmaceutical research and development services; research in the field of genetic modifiers and related therapeutics; research in the field of genetic variations linked to medical diseases or conditions; research in the field of variant functionalization.

Maze Therapeutics, Inc.

Representative: Joyce Liou of Morrison & Foerster LLP, 425 Market Street, San Francisco CA 94105, UNITED STATES OF AMERICA